In recent years, new biomarkers have been developed in blood, urine, and tissue for the more sensitive and specific diagnosis of prostate cancer. These markers are crucial for improving diagnostic accuracy, reducing unnecessary biopsies, and enhancing patient follow-up. In developed countries, specific tests offered for the benefit of patients include the PHI index and 4K score in serum; PCA3, SelectMDx, and ExoDx in urine; and ConfirmMDx in tissue. These tools significantly contribute to patient care by helping detect prostate cancers before they spread, preventing avoidable biopsies, and identifying patients who require repeat biopsies.